Biosimilars LatAm – Colombia 2024
The 2024 edition in Colombia focuses on facilitating local biosimilar production through the exploration of external expertise and successful industry practices. This forum serves as a platform for professionals to engage in strategic discussions aimed at advancing biosimilar development in the region.
La edición 2024 en Colombia se centra en facilitar la producción local de biosimilares mediante la exploración de la experiencia de expertos externos y prácticas exitosas de la industria. Este foro sirve como plataforma para que los profesionales participen en discusiones estratégicas destinadas a avanzar en el desarrollo de biosimilares en la región.
Industry Executives from Latam
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Business Development
Plan Your 1-to-1 Meetings with JackLeckerman App
1. JackLeckerman App: Login & Meeting Notifications
Download the JackLeckerman App and sign up.
Check your email for the login details, or use the “Forgot Password” option to retrieve them.
You will receive meeting reminders on your mobile over the 2 days.
These reminders will include meeting requests, meeting confirmations, and messages from other attendees and the coordinator.
2. Attendee list to Plan Your Meetings
Browse the attendee list and select someone for a 10-minute 1-to-1 Meeting request.
Meeting requests close one hour before each Networking session in the program.
3. Managing Meeting Requests, Your Meetings Schedule
Accept or decline meeting requests through the “Meetings” button.
Check your scheduled meetings for the upcoming networking break.
4. Meeting Point Location in the Coffee Break Area
Go to the coffee break area and find the table number to meet your colleague
Program at a Glance
Regulatory Updates in Colombia
Exploring the Benefits of Contract Research Operations in Colombia
Key Note: Unveiling the Keys to Local Production in LatAm
COFEPRIS Certainty Strategy Implementation
In Mexico, COFEPRIS is currently undertaking a strategic initiative to provide regulatory certainty to pharmaceutical companies, enabling them to introduce medical innovations and drive productive development in the Mexican market. The 2022−2030 agenda aims to foster competitiveness, industrial and commercial growth, and ensure access to safe and high-quality healthcare products. The implementation of this strategy focuses on harmonising regulatory approaches with other agencies, involving the public, private and social sectors, and compliance with ICH guidelines, among other factors. The success of this initiative will play a crucial role in fostering the widespread adoption of biosimilars throughout Latin America.
The Success of Brazilian PDPs in Local Production
Invited: Ministry of Health of Brazil
Health Authorities Successes Accross the Globe
Invited: Regulatory Agencies of Reference & PAHO
Full Programme in the PDF Agenda
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros according to preliminary figures. At the end of 2019, more than 9,000 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
We are a vibrant science and technology company. Science is at the heart of everything we do, it drives the discoveries we make and the technologies we create. For more than 350 years, curiosity has been driving us to deliver excellence to patients and customers – and to imagine the future.